Journal ArticleDOI
Outcomes after laser versus combined laser and bevacizumab treatment for type 1 retinopathy of prematurity in zone i.
Je Moon Yoon,Dong Hoon Shin,Sang Jin Kim,Don-Il Ham,Se Woong Kang,Yun Sil Chang,Won Soon Park +6 more
Reads0
Chats0
TLDR
In Type 1 retinopathy of prematurity in Zone I, intravitreal bevacizumab with concomitant or deferred laser therapy yielded a better anatomical outcome than conventional laser therapy alone.Abstract:
PURPOSE To investigate the anatomical and refractive outcomes in patients with Type 1 retinopathy of prematurity in Zone I. METHODS The medical records of 101 eyes of 51 consecutive infants with Type 1 retinopathy of prematurity in Zone I were analyzed. Infants were treated by conventional laser photocoagulation (Group I), combined intravitreal bevacizumab injection and Zone I sparing laser (Group II), or intravitreal bevacizumab with deferred laser treatment (Group III). The proportion of unfavorable anatomical outcomes including retinal fold, disc dragging, retrolental tissue obscuring the view of the posterior pole, retinal detachment, and early refractive errors were compared among the three groups. RESULTS The mean gestational age at birth and the birth weight of all 51 infants were 24.3 ± 1.1 weeks and 646 ± 143 g, respectively. In Group I, an unfavorable anatomical outcome was observed in 10 of 44 eyes (22.7%). In contrast, in Groups II and III, all eyes showed favorable anatomical outcomes without reactivation or retreatment. The refractive error was less myopic in Group III than in Groups I and II (spherical equivalent of -4.62 ± 4.00 D in Group I, -5.53 ± 2.21 D in Group II, and -1.40 ± 2.19 D in Group III; P < 0.001). CONCLUSION In Type 1 retinopathy of prematurity in Zone I, intravitreal bevacizumab with concomitant or deferred laser therapy yielded a better anatomical outcome than conventional laser therapy alone. Moreover, intravitreal bevacizumab with deferred laser treatment resulted in less myopic refractive error.read more
Citations
More filters
Journal ArticleDOI
VEGFR1 signaling in retinal angiogenesis and microinflammation
Akiyoshi Uemura,Marcus Fruttiger,Patricia A. D'Amore,Sandro De Falco,Antonia M. Joussen,Florian Sennlaub,Lynne R. Brunck,K. T. M. Johnson,George N. Lambrou,Kay D. Rittenhouse,Thomas Langmann +10 more
TL;DR: The ability of the VEGFR1 ligands (VEGF-A, PlGF, and VEGF-B) to compete against each other for receptor binding and to heterodimerize complicates our understanding of the relative contribution of VEG-1 signaling alone toward the pathologic processes seen in diabetic retinopathy, retinal vascular occlusions, retynopathy of prematurity, and age-related macular degeneration as mentioned in this paper.
Journal ArticleDOI
Macular Structures, Optical Components, and Visual Acuity in Preschool Children after Intravitreal Bevacizumab or Laser Treatment
Yung-Sung Lee,Lai-Chu See,Shu-Hao Chang,Nan-Kai Wang,Yih-Shiou Hwang,Chi-Chun Lai,Kuan-Jen Chen,Wei-Chi Wu,Wei-Chi Wu +8 more
TL;DR: Compared with laser therapy, IVB-treated eyes were associated with deeper anterior chamber depths and thinner foveal, parafoveal and perifoveal thicknesses, and better uncorrected visual acuity.
Journal ArticleDOI
Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in Type-1 and threshold retinopathy of prematurity (ROP).
TL;DR: It is suggested that laser treatment may be more efficacious than anti-VEGF treatment in type-1 and threshold ROP, but the results of this meta-analysis also suggest that Laser treatment may cause more eye complications and increase myopia.
Journal ArticleDOI
Evolving Concepts in the Management of Retinopathy of Prematurity
Paul Sternberg,Alia K. Durrani +1 more
TL;DR: The diagnosis and management of ROP has changed over the past 40 years; the role of anti-VEGF therapy remains to be established in current treatment strategies; Screening for initial disease and progression will likely be impacted by the increasing prevalence of telemedicine and relative shortage of clinicians.
Journal ArticleDOI
Retinopathy of Prematurity: How to Prevent the Third Epidemics in Developing Countries.
Rajvardhan Azad,Claire E Gilbert,Anil Gangwe,Peiquan Zhao,Wei-Chi Wu,Wei-Chi Wu,Puja Sarbajna,Anand Vinekar +7 more
TL;DR: Current strategies include adoption of national screening guidelines, telemedicine, integrating vision rehabilitation and software innovations in the form of artificial intelligence, which overviews some of these aspects of ROP management.
References
More filters
Journal ArticleDOI
Neonatal Outcomes of Extremely Preterm Infants From the NICHD Neonatal Research Network
Barbara J. Stoll,Nellie I. Hansen,Edward F. Bell,Seetha Shankaran,Abbot R. Laptook,Michele C. Walsh,Ellen C. Hale,Nancy S. Newman,Kurt Schibler,Waldemar A. Carlo,Kathleen A. Kennedy,Brenda B. Poindexter,Neil N. Finer,Richard A. Ehrenkranz,Shahnaz Duara,Pablo J. Sánchez,T. Michael O'Shea,Ronald N. Goldberg,Krisa P. Van Meurs,Roger G. Faix,Dale L. Phelps,Ivan D. Frantz,Kristi L. Watterberg,Shampa Saha,Abhik Das,Rosemary D. Higgins +25 more
TL;DR: Although the majority of infants with GAs of ≥24 weeks survive, high rates of morbidity among survivors continue to be observed.
Journal ArticleDOI
Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity
TL;DR: Intravitreal bevacizumab monotherapy, as compared with conventional laser therapy, in infants with stage 3+ retinopathy of prematurity showed a significant benefit for zone I but not zone II disease, and conventional laser Therapy led to permanent destruction of the peripheral retina.
Journal ArticleDOI
Improved Survival Rates With Increased Neurodevelopmental Disability for Extremely Low Birth Weight Infants in the 1990s
TL;DR: The improved survival rates in the 1990s occurred with an increased risk of significant neurodevelopmental impairment, and prospective parents of extremely low birth weight infants should be advised of this substantial risk, to facilitate decision-making in the delivery room.
Journal ArticleDOI
Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control.
TL;DR: The reasons for this "third epidemic" of ROP are discussed as well as strategies for control, including the need for locally relevant, evidence based criteria which ensure that all babies at risk are examined.
Journal ArticleDOI
Characteristics of Infants With Severe Retinopathy of Prematurity in Countries With Low, Moderate, and High Levels of Development: Implications for Screening Programs
Clare Gilbert,Alistair R. Fielder,Luz Gordillo,Graham E. Quinn,Renato Semiglia,Patricia Visintin,Andrea Zin +6 more
TL;DR: These findings suggest that larger, more mature infants are developing severe ROP in countries with low/moderate levels of development compared with highly developed countries.